Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

NCT01931098 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

NIH

Sponsor class

Conditions

Glioblastoma
Glioblastoma Multiforme
Gliosarcoma
Brain Neoplasms
Central Nervous System Neoplasms

Interventions

DRUG: topotecan
DRUG: pazopanib

Sponsor

National Cancer Institute (NCI)